Captrust Financial Advisors Verastem, Inc. Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$1.02 - $1.83 $1 - $1	-1 Reduced 0.05%	2,110 $2,000
Q2 2022 Aug 16, 2022	BUY	$1.02 - $1.83 $1 - $1	1 Added 0.05%	2,111 $2,000
Q1 2022 May 16, 2022	SELL	$1.06 - $2.1 $1 - $2	-1 Reduced 0.05%	2,110 $3,000
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $1 - $2	1 Added 0.05%	2,111 $5,000
Q2 2020 Aug 14, 2020	BUY	$1.69 - $4.2 $3,565 - $8,862	2,110 New	2,110 $4,000
Q4 2019 Feb 14, 2020	SELL	$0.86 - $1.44 $86 - $144	-100 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.79 - $4.09 $279 - $409	100 New	100 $0

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.25B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.